Should Labcorp Stock Stay in Your Portfolio Right Now?
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
Here's Why Labcorp (LH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'
Labcorp Holdings Inc., a leader in life sciences and diagnostics, is efficiently managing its financials and focusing on core strengths for long-term growth, warranting a “Hold” rating. Competitive advantages include large scale, diversified business model, strong industry relationships, and operational efficiency, driving strong revenue and margin expansion. Recent strategic initiatives like the Fortrea spin-off, Invitae acquisition, and SYNLAB stake enhance Labcorp's core business and future growth prospects.
Why Labcorp (LH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Investors Undervaluing Labcorp (LH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Labcorp (LH) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Labcorp (LH) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH ) Q4 2024 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Christian O'Donnell - IR Adam Schechter - Chairman and CEO Julia Wang - EVP and CFO Conference Call Participants Michael Cherny - Leerink Partners Jack Meehan - Nephron Research Lisa Gill - JP Morgan Erin Wright - Morgan Stanley Andrew Brackmann - William Blair Pito Chickering - Deutsche Bank Patrick Donnelly - Citi Kevin Caliendo - UBS David Westenberg - Piper Sandler Tycho Peterson - Jefferies Operator Good day, and thank you for standing by. Welcome to Labcorp's Fourth Quarter 2024 Conference Call [Operator Instructions].
Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook
Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39.
Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Labcorp (LH) Q4 Earnings and Revenues Surpass Estimates
Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago.
